10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
Illumina Inc. (ILMN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | GuardCap Asset Management Guardian Capital | 2,724,818 | $355,343,515 | +48% | 4.83% |
| 2. | Corvex Capital Keith Meister | 2,280,798 | $297,438,867 | -1% | 11.55% |
| 3. | Millennium Management Israel Englander | 1,464,151 | $190,939,932 | -2% | 0.09% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,239,763 | $161,677,494 | +67% | 0.19% |
| 5. | Renaissance Technologies Jim Simons | 1,083,960 | $141,359,224 | +9% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $137.18 | 692 | Officer, Director | 14,861 | 2024-02-22 | Filing | |
| $135.69 | 1,553 | Officer, Director | 14,169 | 2024-02-22 | Filing | |
| $134.91 | 5,085 | Officer, Director | 12,616 | 2024-02-22 | Filing | |
| $43.87 | 315 | Director | 670 | 2012-04-18 | Filing | |
| $36.54 | 809 | Director | 809 | 2012-01-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $112.84 | 315 | Officer | 8,314 | 2023-11-07 | Filing | |
| $167.04 | 500 | Officer | 45,524 | 2023-08-22 | Filing | |
| $190.08 | 500 | Officer | 46,022 | 2023-07-24 | Filing | |
| $200.00 | 500 | Officer | 46,522 | 2023-06-22 | Filing | |
| $209.67 | 1,676 | Officer | 47,022 | 2023-05-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,687,511.364 | $2,531,176,150 | 0.05% | |
| 2. | 13,675,482.972 | $1,852,309,607 | 0.04% | |
| 3. | 7,071,092.86 | $957,761,644 | 2.76% | |
| 4. | 6,911,877.248 | $936,196,292 | 0.04% | |
| 5. | 5,423,490.532 | $734,598,076 | 0.6% |
News See All
UBS' Top Quant Stocks In AI, IT, Healthcare & Other Sectors: Top 33 Stocks In All Sectors
With the third quarter of the 2024 earnings season underway, Wall Street is dealing with a changing stock market environment.
Here’s Why You Should Invest in Illumina (ILMN)
Baron Funds, an investment management firm, released its “Baron Global Advantage Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Illumina, Inc. (NASDAQ:ILMN) Q3 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Third Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
Is this the Best Time to Add Illumina (ILMN)?
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Illumina, Inc. (ILMN): A Bull Case Theory
We came across a bullish thesis on Illumina, Inc. (ILMN) on Ocean Road Capital’s Substack by Ocean Road Capital. In this article, we will summarize the bulls’ thesis on ILMN.
10 Cheap Robotics Stocks To Buy
The progress of Western civilization is built on industrialization.
Shake-Up Alert: 40 Companies Facing Activist Pressure
The equity market has been on a roll, rallying by 10% in the first half of 2024, adding to the 24% gain registered in 2024.
Illumina, Inc. (NASDAQ:ILMN) Q2 2024 Earnings Call Transcript
Operator: Good day ladies and gentlemen and welcome to the Second Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here’s Why You Should Add Illumina (ILMN) to Your Portfolio
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here.